Clinical-stage cardiovascular and pulmonary hypertension drug development
Strategic Profile
The company completed randomization of more than 230 patients in the Phase 3 LEVEL study positioned to deliver topline data in third quarter 2026, with Piper Sandler raising its price target from $20 to $50 in June 2026, reflecting growing confidence in the company's drug development pipeline and impending clinical milestones for TNX-103. Cash position of $118.8 million is expected to fund operations through at least Q1 2028.
Cyborg Score Rationale
Tenax is advancing a first-in-class oral levosimendan for a large unmet cardiopulmonary market with compelling Phase 3 data readout approaching in Q3 2026. Strong cash runway and recent bullish analyst revisions indicate market conviction, though early-stage biotech execution risk and regulatory approval uncertainty remain material concerns.
Top Insights
(June 2026) Piper Sandler raised price target to $50 on growing confidence in clinical pipeline and TNX-103 development milestones
(May 2026) Strengthened leadership team with new Chief Financial Officer, Chief Commercial Officer, and Executive VP of Clinical Development appointments
(Q1 2026) Completed randomization of 230+ patients in Phase 3 LEVEL study; topline data expected Q3 2026
Targeting largest unmet PH-HFpEF market (~1.4M US patients) with no approved therapies; oral formulation represents potential competitive advantage
Named Competitors
Treprostinil — Pulmonary hypertension therapy
Ambrisentan — Endothelin receptor antagonist for pulmonary hypertension
Cardiac/Pulmonary Therapies — Rare cardiovascular disease development (acquired by Merck)
Recent Developments
(June 2026) Piper Sandler raised price target from $20 to $50, citing confidence in drug development pipeline
(May 2026) Appointed So-Young Kim as Executive VP of Clinical Development and Strategy, bringing Bayer cardiovascular experience
(May 2026) Appointed Timothy Healey as Chief Commercial Officer and Thomas Staab as Chief Financial Officer
(Q1 2026) LEVEL Phase 3 study randomization completed with 230+ patients; Phase 3 LEVEL-2 trial ongoing
Open the full interactive TENAX THERAPEUTICS, INC. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.